Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
A deal with Jacobio is worth $100m up front.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
